3 results
Approved WMOCompleted
Primary: treatment effect of TKI258 in combination with fulvestrant vs. fulvestrant plus placebo on Progression-Free Survival (voor for each of the 2 groups, namely FGF pathway amplified and regardless of FGF pathway amplification status).Secondary…
Approved WMOWill not start
To collect long term data on safety and tolerability of dovitinib monotherapy.
Approved WMOCompleted
To establish whether niraparib single agent treatment in advanced BRCA1-like, HER2 negative breast cancer patients deserves to be further studied